Caspofungin

CHEMBL1630575 Phase 4 Approved Small molecule

Half-Life

—

Bioavailability

—

Protein Binding

—

Molecular Weight

1093.3 g/mol

LogP

0.3

Phase

4

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Molecular Weight

1093.3000 g/mol

LogP

0.30

TPSA

412.00 Å²

Lipinski RO5

Fail

Therapeutic Areas

Bladder Cancer Breast Cancer Chronic Obstructive Pulmonary Disease Colorectal Cancer Leukemia Lymphoma Non-Alcoholic Fatty Liver Disease Non-Small Cell Lung Cancer Obesity Ovarian Cancer Pancreatic Cancer Prostate Cancer Thyroid Cancer

Pharmacokinetics (PK)

Pharmacodynamics (PD)

2D Structure

SVG PNG

Cite this structure

Embed this structure

SMILES

CC[C@H](C)C[C@H](C)CCCCCCCCC(=O)N[C@H]1C[C@@H](O)[C@@H](NCCN)NC(=O)[C@@H]2[C@@H](O)CCN2C(=O)[C@H]([C@H](O)CCN)NC(=O)[C@H]([C@H](O)[C@@H](O)c2ccc(O)cc2)NC(=O)[C@@H]2C[C@@H](O)CN2C(=O)[C@H]([C@@H](C)O)NC1=O

InChI

InChI=1S/C52H88N10O15/c1-5-28(2)24-29(3)12-10-8-6-7-9-11-13-39(69)56-34-26-38(68)46(55-22-21-54)60-50(75)43-37(67)19-23-61(43)52(77)41(36(66)18-20-53)58-49(74)42(45(71)44(70)31-14-16-32(64)17-15-31)59-48(73)35-25-33(65)27-62(35)51(76)40(30(4)63)57-47(34)72/h14-17,28-30,33-38,40-46,55,63-68,70-71H,5-13,18-27,53-54H2,1-4H3,(H,56,69)(H,57,72)(H,58,74)(H,59,73)(H,60,75)/t28-,29+,30+,33+,34-,35-,36+,37-,38+,40-,41-,42-,43-,44-,45-,46-/m0/s1

Molecular Formula

C52H88N10O15

HBD / HBA

16 / 18

Rotatable Bonds

23

Heavy Atoms

77

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Frequently Asked Questions

An antifungal agent belonging to the echinocandin class that inhibits the synthesis of beta-1,3-D-glucan, an essential component of the fungal cell wall not found in human cells. It is used intravenously to treat invasive Aspergillus and Candida infections in patients who are unresponsive to or intolerant of other antifungals. Its targeted mechanism results in a favorable tolerability profile compared to older antifungals.

Yes, Caspofungin is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1630575. Open-access bioactivity database.
PubChem — National Center for Biotechnology Information (NCBI). CID 16119814. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

PillFYI

Looking for patient-friendly information?

Caspofungin on PillFYI

Structure

Quick Data

Formula: C52H88N10O15
Synonyms: 1

External Links

Cite

BibTeX, APA, MLA, Chicago, IEEE, Harvard

Medical Disclaimer

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.